{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/prescribing-information/salicylic-acid/","result":{"pageContext":{"chapter":{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid","depth":2,"htmlHeader":"<!-- begin field c5483134-106d-47f5-82a3-7ace094cb8dc --><h2>Salicylic acid</h2><!-- end field c5483134-106d-47f5-82a3-7ace094cb8dc -->","summary":"","htmlStringContent":"<!-- begin item 6f2f2970-baa8-423a-b929-cff93edddb47 --><!-- end item 6f2f2970-baa8-423a-b929-cff93edddb47 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ce3be64b-a968-59e2-b206-5a055de98330","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"08ccafff-e4b0-5cde-aafc-1e04231481b2","slug":"availability-choice","fullItemName":"Availability and choice","depth":3,"htmlHeader":"<!-- begin field a7da391a-5394-4575-bd20-970cf893ec5c --><h3>Availability and choice</h3><!-- end field a7da391a-5394-4575-bd20-970cf893ec5c -->","summary":"","htmlStringContent":"<!-- begin item 14ee330e-0ba5-4465-a883-04337804da13 --><!-- begin field 00575bff-060a-4cce-8f81-64cd8e272d41 --><ul><li><strong>Products suitable for the scalp include:</strong><ul><li>Sebco<sup>®</sup> scalp ointment (coal tar 12%, salicylic acid 2%, sulphur 4%, coconut oil).</li><li>Psorin<sup>®</sup> scalp gel (dithranol 0.25%, salicylic acid 1.6%).</li><li>Capasal<sup>®</sup> shampoo (coal tar 1%, coconut oil 1%, salicylic acid 1%).</li><li>Meted<sup>®</sup> shampoo (salicylic acid 3%, sulphur 5%).</li></ul></li><li><strong>Products suitable for plaques on the trunk and limbs include:</strong><ul><li>Psorin<sup>®</sup> ointment (dithranol 0.11%, coal tar 1%, salicylic acid 1.6%).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>]</p><!-- end field 00575bff-060a-4cce-8f81-64cd8e272d41 --><!-- end item 14ee330e-0ba5-4465-a883-04337804da13 -->","subChapters":[]},{"id":"d1f0049e-ab8a-5dad-8ad8-d90c9bbf21cd","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 294f3f57-948f-4555-8800-e92ef88dc643 --><h3>Contraindications and cautions</h3><!-- end field 294f3f57-948f-4555-8800-e92ef88dc643 -->","summary":"","htmlStringContent":"<!-- begin item c8cd1389-a404-43e5-9545-77b1aa04dc49 --><!-- begin field ec99ee72-bbf6-4df3-8a49-3e34b360f260 --><p><strong>Do not prescribe topical salicylic acid preparations for people:</strong></p><ul><li>Who are allergic to aspirin.</li><li>Who have inflamed or broken skin.</li></ul><p><strong>Prescribe topical salicylic with caution:</strong></p><ul><li>If applied on large areas of skin — risk of salicylate toxicity.</li><li>To people who are pregnant or breastfeeding — use on limited areas for a limited time period.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Schaefer, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field ec99ee72-bbf6-4df3-8a49-3e34b360f260 --><!-- end item c8cd1389-a404-43e5-9545-77b1aa04dc49 -->","subChapters":[]},{"id":"d7aefbc6-d3af-50e1-bc24-1201d071274a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1d386124-046d-4f53-b2f4-319cfd12a0c0 --><h3>Adverse effects</h3><!-- end field 1d386124-046d-4f53-b2f4-319cfd12a0c0 -->","summary":"","htmlStringContent":"<!-- begin item a09ae9a2-7d96-422c-8784-09232f8c85d4 --><!-- begin field 4cdaebd8-bcb9-445d-ac7a-d63def44212f --><ul><li>Topical salicylic acid may cause irritation and excessive drying of the skin.<ul><li>Advise the person to avoid contact with their mouth, mucous membranes, and eyes; and to wash their hands immediately after use.</li></ul></li><li>Salicylate toxicity may occur if large areas of the skin are treated.<ul><li>Salicylic acid preparations should not be applied to more than 20% of the body surface area.</li><li>The symptoms of salicylic acid toxicity include frontal headache, tinnitus, nausea and vomiting.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 4cdaebd8-bcb9-445d-ac7a-d63def44212f --><!-- end item a09ae9a2-7d96-422c-8784-09232f8c85d4 -->","subChapters":[]},{"id":"cb5a0d03-6d4a-5740-aa25-fea0395eddfa","slug":"application","fullItemName":"Application","depth":3,"htmlHeader":"<!-- begin field 9862e2de-7c8b-4d13-b762-02cacba80115 --><h3>Application</h3><!-- end field 9862e2de-7c8b-4d13-b762-02cacba80115 -->","summary":"","htmlStringContent":"<!-- begin item 092bac3a-1be5-4cbb-9c04-f11593b9ce8c --><!-- begin field 282a389f-3de3-412f-b0c9-23b9afdeced8 --><p><strong>Salicylic acid preparations should not be applied to more than 20% of the body surface area, due to the risk of systemic salicylate toxicity.</strong></p><ul><li><strong>Sebco<sup>®</sup> scalp ointment </strong>should be applied in the following way:<ul><li>The hair is parted in sections and the treatment rubbed along the exposed areas, working around the hair. Assistance may be needed to apply it correctly to the top of the head.</li><li>It is left on for 1 hour and then washed off with a detergent shampoo or a coal tar shampoo (for example Polytar<sup>®</sup>, Alphosyl 2:1<sup>®</sup>, or Capasal<sup>®</sup>).<ul><li>If psoriasis is severe, advise the person it should be applied once a day for the first 3–7 days, and once a week thereafter.</li><li>If scale is thick and adherent the person should apply it, then leave it on overnight under occlusion (for example using a shower cap); it can then be washed off in the morning with a detergent shampoo or a coal tar shampoo. Note: this method of application is off-label.</li></ul></li></ul></li><li><strong>Other salicylic acid products </strong>should be used in the following way:<ul><li>Psorin<sup>®</sup> scalp gel — applied every other day for 10–20 minutes (the maximum dose is daily application for 1 hour), then washed off.</li><li>Capasal<sup>®</sup> shampoo — used as a shampoo, daily if necessary.</li><li>Meted<sup>®</sup> shampoo — used as a shampoo, at least twice a week.</li><li>Zinc and salicylic acid paste BP (Lassar's paste) — applied twice a day.</li><li>Psorin<sup>®</sup> ointment — applied twice a day.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 282a389f-3de3-412f-b0c9-23b9afdeced8 --><!-- end item 092bac3a-1be5-4cbb-9c04-f11593b9ce8c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}